

Important Product Information

Chlorhexidine Acetate 0.015% w/v and Cetrimide 0.15% w/v, Irrigation Solution, Chlorhexidine Acetate 0.02% w/v for Irrigation, Chlorhexidine Acetate B.P. 0.05% w/v for Irrigation

FA-2026-006

March 11, 2026

Dear Sir/Madam,

Baxter Healthcare Corporation, in agreement with the MHRA is issuing an Important Product Information letter for the products listed below to inform you of the important updates made to the Product Information Leaflets (PIL).

Details:

- Chlorhexidine Acetate 0.015% w/v and Cetrimide 0.15% w/v, Irrigation Solution is for general topical use, combining antibacterial activity against a wide range of vegetative gram-positive and gram-negative bacteria with useful cleansing properties. The solution is recommended for the cleansing and disinfection of wounds and the antiseptic treatment of burns and is recommended for swabbing in obstetrics, gynaecology and urology.
- Chlorhexidine Acetate BP is a disinfectant which is effective against a wide range of vegetative gram-positive and gram-negative bacteria. Chlorhexidine Acetate BP 0.02% w/v for Irrigation is recommended for general topical use when antibacterial irrigation is indicated, including wound and burn irrigation and for the disinfection of respirators.
- Chlorhexidine must not come into contact with the eye due to the risk of visual damage. If it comes into contact with the eyes, it must be washed out immediately and thoroughly with water. Patients shall be instructed about this and ask for medical advice promptly in case of any irritation, redness or pain in the eye, or visual disturbance. Serious cases of persistent corneal injury (injury to the surface of the eye) potentially requiring corneal transplant have been reported when similar products have accidentally come in contact with the eye during surgical procedures, in patients under general anaesthesia (deep painless sleep). The specific batches listed in the table below do not contain this updated verbiage in the PIL.

eMC links

The updated PILs can be accessed on the Electronic Medicines Compendium (eMC):

Chlorhexidine and Cetrимide: [Chlorhexidine Acetate 0.015% w/v and Cetrимide 0.15% w/v, Irrigation Solution - Patient Information Leaflet \(PIL\) - \(emc\) | 1809](#) or navigate to: www.medicines.org.uk/emc/product/1809/pil

Chlorhexidine Acetate 0.02%: [Chlorhexidine Acetate BP 0.02% w/v for Irrigation - Patient Information Leaflet \(PIL\) - \(emc\) | 1810](#) or navigate to: www.medicines.org.uk/emc/product/1810/pil

Chlorhexidine Acetate 0.05%: [Chlorhexidine Acetate BP 0.05% w/v for Irrigation - Patient Information Leaflet \(PIL\) - \(emc\) | 1811](#) or navigate to: www.medicines.org.uk/emc/product/1811/pil

Affected Product (to be adapted locally)

Product Code	Description	GTIN	Lot Number	Expiration Date
FKF7774	Chlorhexidine Acetate 0.015% w/v and Cetrимide 0.15% w/v, Irrigation Solution	Carton GTIN Number: 55413760020315	24J31BB1A	28-Sep-2026
			24L09BB1A	28-Nov-2026
			24L23BB2B	28-Nov-2026
			25B19BB1A	28-Jan-2027
			25C05BB1A	28-Feb-2027
FKF7981	Chlorhexidine Acetate 0.02% w/v for Irrigation	Carton GTIN Number: 55413760020353 Unit GTIN Number: 05413760020358	24L04BB1A	28-Nov-2026
			25B10BB2B	28-Jan-2027
			25D15BB1A	28-Mar-2027
FKF7984	Chlorhexidine Acetate B.P. 0.05% w/v for Irrigation	Carton GTIN Number: 55413760020377 Unit GTIN Number: 05413760020372	24K28BB1A	28-Oct-2026
			24L16BB1A	28-Nov-2026
			25B26BB1A	28-Jan-2027
			25C12BB1A	28-Feb-2027

Actions to be Taken by Customers

1. If you distribute this product to other facilities or to departments within your institution, please forward a copy of this communication to those locations.
2. Complete the enclosed customer reply form and return it to Baxter by scanning and e-mailing it to (uk_shs_fca@baxter.com.) even if you don't have any inventory. Returning the customer reply form promptly will confirm your receipt of this notification and prevent you from receiving repeat notices.
3. If you purchased this product from a distributor, please note that the Baxter customer reply form is not applicable. If a reply form is provided by your distributor or wholesaler, please return it to the supplier according to their instructions.
4. If you are a dealer, wholesaler, distributor/reseller, or original equipment manufacturer (OEM) that distributed any affected product to other facilities, please notify your customers of this Important Product Information in accordance with your customary procedures.

Call for Reporting

Please continue to report suspected adverse drug reactions (ADRs) to the MHRA through the Yellow Card scheme [Yellow Card | Making medicines and medical devices safer](#) (<https://yellowcard.mhra.gov.uk>)

Contact Baxter Product Surveillance via the [Baxter - Product Feedback Portal \(https://productfeedback.baxter.com\)](https://productfeedback.baxter.com) to report any issue.

Further Information and Support

For general questions regarding this communication or any product issue you are experiencing, contact Baxter at uk_shs_fca@baxter.com.

The local Ministry of Health (MOH) has been notified of this action.

We apologise for any inconvenience this may cause you and your staff.

Sincerely,



Name: Lindsey Hilton

Title: Business Unit Head, Infusion Therapies & Technologies and Pharma
Baxter Healthcare Limited

Enclosures: Baxter Customer Reply Form